Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Saratin is a **recombinant protein** originally isolated from the saliva of the medicinal leech (*Hirudo medicinalis*)[4]. It is a **12 kDa protein** that acts as an **inhibitor of von Willebrand factor (vWF)**, thereby **inhibiting platelet-collagen interactions** and **reducing platelet aggregation**[2][4]. Saratin has shown anti-inflammatory and anti-platelet effects and is being investigated for indications such as **antithrombotic therapy**, prevention of **platelet adhesion**, and **intimal hyperplasia** after vascular interventions[2][3][4]. It has also been evaluated preclinically for use in ophthalmic surgery to prevent post-surgical fibrosis[3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on saratin.